The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis
Official Title: Randomized Double Blind Phase I Trial Comparing Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety of Rituximab (Mabscale LLC, Russia)+ Methotrexate+ Folic Acid and MabThera® Methotrexate+ Folic Acid in Adult Patients With Moderate or Severe Rheumatoid Arthritis With Insufficient Response to Treatment Tumor Necrosis Factor (TNF-α)
Study ID: NCT06175338
Brief Summary: A randomised, double blind, parallel group, multicentre study to compare the pharmacokinetics, pharmacodynamics, immunogenicity and safety of Rituximab (Mabscale LLC, Russia) versus MabThera® in patients with rheumatoid arthritis.
Detailed Description: RIT-1/01092021 is a double-blind randomized, parallel group, multicenter clinical trial comparing pharmacokinetics, pharmacodynamics, immunogenicity and safety of Rituximab (Mabscale LLC, Russia) and MabThera® in adult patients with moderate or severe rheumatoid arthritis with insufficient response to treatment tumor necrosis factor (TNF-α) inhibitors receiving background treatment with methotrexate. The purpose of the study is to demonstrate equivalence of pharmacokinetics, pharmacodynamics, immunogenicity and safety of Rituximab (Mabscale LLC, Russia) and MabThera®. The study will take place across approximately 30 study sites in Russia in order to randomize 208 patients. Rituximab is a monoclonal antibody currently being developed by Mabscale LLC, as a proposed biosimilar to MabThera®, which is approved as treatment in case of insufficient response or toxicity to treatment tumor necrosis factor (TNF-α) inhibitors receiving background treatment with methotrexate. This randomized equivalence study is designed to meet the regulatory requirement for approval of a biosimilar product.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Immanuel Kant Baltic Federal University, Kaliningrad, , Russian Federation
Scientific-Research Medical Complex Your Health, Kazan, , Russian Federation
LLC "Medical Center Revma-Med", Kemerovo, , Russian Federation
LLC "Korolev Family Clinic №4", Korolev, , Russian Federation
Moscow City Clinical Hospital №1, Moscow, , Russian Federation
V.A. Nasonova Research Institute of Rheumatology, Moscow, , Russian Federation
Orenburg State Medical University, Orenburg, , Russian Federation
JSC "Northwestern Center for Evidence-Based Medicine", Saint-Petersburg, , Russian Federation
LLC "Interleukin", Saint-Petersburg, , Russian Federation
Medical center "Capital-Polis", Saint-Petersburg, , Russian Federation
Saratov State Medical University, Saratov, , Russian Federation
LLC "Biomed", Vladimir, , Russian Federation